BR0314603A - Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos - Google Patents
Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secosInfo
- Publication number
- BR0314603A BR0314603A BR0314603-0A BR0314603A BR0314603A BR 0314603 A BR0314603 A BR 0314603A BR 0314603 A BR0314603 A BR 0314603A BR 0314603 A BR0314603 A BR 0314603A
- Authority
- BR
- Brazil
- Prior art keywords
- dry eye
- treatment
- cytokine synthesis
- eye disorders
- synthesis inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
"USO DE INIBIDORES DA SìNTESE DE CITOQUINA PARA O TRATAMENTO DE DISTúRBIOS DE OLHOS SECOS". A presente invenção refere-se a inibidores da síntese de citoquina em células residentes da superfície ocular, não-imunes, que são úteis para tratar distúrbios de olhos secos e outros distúrbios que requerem a umidificação dos olhos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41246302P | 2002-09-20 | 2002-09-20 | |
PCT/US2003/026689 WO2004026406A1 (en) | 2002-09-20 | 2003-08-26 | Use of cytokine synthesis inhibitors for the treatment of dry eye disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0314603A true BR0314603A (pt) | 2005-07-26 |
Family
ID=32030872
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0314603-0A BR0314603A (pt) | 2002-09-20 | 2003-08-26 | Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos |
Country Status (14)
Country | Link |
---|---|
US (2) | US7026296B2 (pt) |
EP (1) | EP1542768A1 (pt) |
JP (1) | JP2006502183A (pt) |
KR (1) | KR20050057175A (pt) |
CN (1) | CN1684738A (pt) |
AR (1) | AR041262A1 (pt) |
AU (1) | AU2003278727A1 (pt) |
BR (1) | BR0314603A (pt) |
CA (1) | CA2497977A1 (pt) |
MX (1) | MXPA05003063A (pt) |
PL (1) | PL374700A1 (pt) |
TW (1) | TW200404534A (pt) |
WO (1) | WO2004026406A1 (pt) |
ZA (1) | ZA200502119B (pt) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040082509A1 (en) | 1999-10-12 | 2004-04-29 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
CN1684738A (zh) * | 2002-09-20 | 2005-10-19 | 爱尔康公司 | 细胞因子合成抑制剂用于治疗干眼病的用途 |
MXPA05005101A (es) * | 2002-11-15 | 2005-09-08 | Sangstat Medical Corp | Peptidos de citomodulacion para el tratamiento de cistitis intersticial. |
WO2004093878A1 (en) | 2003-04-16 | 2004-11-04 | Alcon, Inc. | Use of fused pyridazine derivatives for treating dry eye disorders |
PT1682537E (pt) | 2003-11-05 | 2012-06-20 | Sarcode Bioscience Inc | Moduladores de adesão celular |
CN101524351A (zh) * | 2003-12-01 | 2009-09-09 | 沃泰克斯药物股份有限公司 | 使用ice抑制剂治疗感染疾病 |
US20060094753A1 (en) * | 2004-10-29 | 2006-05-04 | Alcon, Inc. | Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases |
US7803824B2 (en) * | 2004-10-29 | 2010-09-28 | Alcon, Inc. | Use of inhibitors of Jun N-terminal kinases to treat glaucoma |
LT2444079T (lt) | 2005-05-17 | 2017-03-27 | Sarcode Bioscience Inc. | Kompozicijos ir būdai, skirti akių sutrikimų gydymui |
AU2006254840B2 (en) | 2005-06-08 | 2012-08-02 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
AU2006261157A1 (en) * | 2005-06-17 | 2006-12-28 | Regenerx Biopharmaceuticals, Inc. | LKKTET and/or LKKTNT peptide compositions and methods |
WO2007031098A1 (en) * | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
CN1939534B (zh) * | 2005-09-27 | 2010-12-01 | 长春金赛药业股份有限公司 | 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂 |
JP2007133001A (ja) * | 2005-11-08 | 2007-05-31 | Seed Co Ltd | コンタクトレンズ用ケア用剤 |
EP2348023B9 (en) | 2005-12-13 | 2017-03-08 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
US7745461B1 (en) | 2006-02-27 | 2010-06-29 | Alcon Research, Ltd. | Method of treating dry eye disorders |
CA2663545A1 (en) * | 2006-09-19 | 2008-03-27 | Phylogica Limited | Neuroprotective peptide inhibitors of ap-1 signaling and uses thereof |
CN101932582B (zh) | 2007-06-13 | 2013-09-25 | 因塞特公司 | 詹纳斯激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐 |
MX2010004281A (es) | 2007-10-19 | 2010-09-10 | Sarcode Corp | Composiciones y metodos para el tratamiento de la retinopatia diabetica. |
WO2009139817A2 (en) | 2008-04-15 | 2009-11-19 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
WO2009143865A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2009143864A1 (en) * | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
WO2010072228A1 (en) | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
CN102458581B (zh) | 2009-05-22 | 2016-03-30 | 因塞特控股公司 | 作为JANUS激酶抑制剂的吡唑-4-基-吡咯并[2,3-d]嘧啶和吡咯-3-基-吡咯并[2,3-d]嘧啶的N-(杂)芳基-吡咯烷衍生物 |
SG176111A1 (en) | 2009-05-22 | 2011-12-29 | Incyte Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
CA2768543C (en) * | 2009-07-28 | 2017-06-20 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
US8378105B2 (en) | 2009-10-21 | 2013-02-19 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
ME02386B (me) | 2010-03-10 | 2016-09-20 | Incyte Holdings Corp | Derivati piperidin-4-il azetidina kao inhibitori jak1 |
KR102303885B1 (ko) | 2010-05-21 | 2021-09-24 | 인사이트 홀딩스 코포레이션 | Jak 저해제에 대한 국소 제형 |
WO2011160653A1 (en) | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
US9150618B2 (en) | 2010-10-14 | 2015-10-06 | Xigen Inflammation Ltd. | Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
EP2640723A1 (en) | 2010-11-19 | 2013-09-25 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
US8691807B2 (en) | 2011-06-20 | 2014-04-08 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
SG11201402347YA (en) * | 2011-11-30 | 2014-06-27 | Xigen Inflammation Ltd | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of dry eye syndrome |
WO2013091670A1 (en) * | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
EP3715345B1 (en) | 2012-07-25 | 2024-04-10 | Novartis AG | Preparation of lfa-1 inhibitor |
EA201590930A1 (ru) | 2012-11-15 | 2015-08-31 | Инсайт Корпорейшн | Лекарственные формы руксолитиниба с замедленным высвобождением |
JP6397831B2 (ja) | 2013-03-06 | 2018-09-26 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤の製造方法及びその中間体 |
CN105307670A (zh) | 2013-06-26 | 2016-02-03 | 埃克西金炎症有限公司 | Jnk信号转导途径的细胞渗透肽抑制剂用于治疗多种疾病的新用途 |
WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
MY195091A (en) | 2013-08-07 | 2023-01-10 | Incyte Corp | Sustained Release Dosage Forms for a JAK1 Inhibitor |
US10813920B2 (en) * | 2013-11-14 | 2020-10-27 | The Doshisha | Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
KR101778004B1 (ko) * | 2015-06-22 | 2017-09-15 | (주) 에빅스젠 | 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물 |
WO2017066758A1 (en) * | 2015-10-15 | 2017-04-20 | The Schepens Eye Research Institute, Inc. | P38 map kinase inhibitors for wound healing |
CN105496955A (zh) * | 2015-12-11 | 2016-04-20 | 北京蓝丹医药科技有限公司 | 一种二氟泼尼酯眼用乳剂及其制备方法 |
JPWO2017110093A1 (ja) | 2015-12-24 | 2018-10-11 | 学校法人同志社 | TGF−βシグナルに起因する障害を治療または予防するための医薬およびその応用 |
WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
CR20200379A (es) | 2018-01-30 | 2021-03-05 | Incyte Corp | Procesos e intermedio para elaborar un inhibidor de jak campo técnico |
CA3095487A1 (en) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Treatment of hidradenitis suppurativa using jak inhibitors |
CA3150975A1 (en) | 2019-06-10 | 2020-12-17 | Incyte Corporation | Topical treatment of vitiligo by a jak inhibitor |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
WO2023150560A1 (en) * | 2022-02-01 | 2023-08-10 | Baylor College Of Medicine | Rxr agonists in eye disorders |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4131651A (en) | 1977-10-25 | 1978-12-26 | Barnes-Hind Pharmaceuticals, Inc. | Treatment of dry eye |
US4409205A (en) | 1979-03-05 | 1983-10-11 | Cooper Laboratories, Inc. | Ophthalmic solution |
US4370325A (en) | 1979-03-30 | 1983-01-25 | Dermik Laboratories | Pharmaceutical compositions and method of treatment |
US4753945A (en) | 1986-02-19 | 1988-06-28 | Eye Research Institute Of Retina Foundation | Stimulation of tear secretion with phosphodiesterase inhibitors |
US4744980A (en) | 1986-04-28 | 1988-05-17 | Holly Frank J | Ophthalmic solution for treatment of dry eye syndrome |
US4883658A (en) | 1986-04-28 | 1989-11-28 | Holly Frank J | Ophthalmic solution for treatment of dry-eye syndrome |
US4818537A (en) | 1986-10-21 | 1989-04-04 | Liposome Technology, Inc. | Liposome composition for treating dry eye |
US4966773A (en) | 1986-11-25 | 1990-10-30 | Alcon Laboratories, Inc. | Topical ophthalmic compositions containing microfine retinoid particles |
US5278151A (en) | 1987-04-02 | 1994-01-11 | Ocular Research Of Boston, Inc. | Dry eye treatment solution |
US4914088A (en) | 1987-04-02 | 1990-04-03 | Thomas Glonek | Dry eye treatment solution and method |
US5075104A (en) | 1989-03-31 | 1991-12-24 | Alcon Laboratories, Inc. | Ophthalmic carboxy vinyl polymer gel for dry eye syndrome |
US5174988A (en) | 1989-07-27 | 1992-12-29 | Scientific Development & Research, Inc. | Phospholipid delivery system |
US5041434A (en) | 1991-08-17 | 1991-08-20 | Virginia Lubkin | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
ZA912797B (en) | 1990-05-29 | 1992-12-30 | Boston Ocular Res | Dry eye treatment process and solution |
ES2084722T3 (es) | 1990-05-29 | 1996-05-16 | Boston Ocular Res | Composicion para tratamiento del ojo seco. |
ZA927277B (en) | 1991-10-02 | 1993-05-19 | Boston Ocular Res | Dry eye treatment process and solution. |
US5290572A (en) | 1992-08-06 | 1994-03-01 | Deo Corporation | Opthalmic composition for treating dry eye |
CZ290266B6 (cs) | 1993-07-02 | 2002-06-12 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem |
US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
US5696166A (en) | 1995-10-31 | 1997-12-09 | Yanni; John M. | Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders |
WO1997020578A1 (en) * | 1995-12-04 | 1997-06-12 | University Of Miami | Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance |
US5958671A (en) | 1996-04-23 | 1999-09-28 | Presidents And Fellows Of Harvard College | Methods and compositions for regulating T cell subsets by modulating transcription factor activity |
JPH1036289A (ja) | 1996-07-24 | 1998-02-10 | Sumitomo Pharmaceut Co Ltd | 神経細胞の変性または死滅抑制剤 |
US5800807A (en) | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
US6043083A (en) * | 1997-04-28 | 2000-03-28 | Davis; Roger J. | Inhibitors of the JNK signal transduction pathway and methods of use |
JPH10330257A (ja) | 1997-06-02 | 1998-12-15 | Senju Pharmaceut Co Ltd | 眼局所用サイトカイン産生抑制剤 |
US5980929A (en) * | 1998-03-13 | 1999-11-09 | Johns Hopkins University, School Of Medicine | Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation |
ES2136581B1 (es) | 1998-05-27 | 2000-09-16 | Uriach & Cia Sa J | Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb. |
DK1037627T3 (da) | 1998-07-14 | 2001-10-01 | Alcon Lab Inc | Anvendelse af 11-(3-dimethylamino-propyliden)-6, 11-dihydrodibenz[b,e]oxepin-2-eddikesyre og af farmaceutisk acceptable salte deraf til fremstillingen af et lægemiddel til behandlingen af non-allergiske... |
WO2000026209A1 (en) | 1998-11-03 | 2000-05-11 | Novartis Ag | Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles |
CN1387502A (zh) | 1999-11-09 | 2002-12-25 | 爱尔康公司 | 15-羟基二十碳四烯酸相关性化合物和使用方法 |
AU8031400A (en) | 1999-11-09 | 2001-06-06 | Alcon Universal Limited | 15-hydroxyeicosatetraenoic acid analogs with enhanced metabolic stability and methods of their use in treating dry eye disorders |
US6458854B2 (en) | 1999-11-09 | 2002-10-01 | Alcon Universal Ltd. | Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use |
DK1228028T3 (da) | 1999-11-09 | 2005-11-14 | Alcon Inc | Hydroxyicosatetraenoatsalte, præparater og fremgangsmåder til anvendelse til behandling af öjentörhedslidelser |
WO2001034129A2 (en) | 1999-11-09 | 2001-05-17 | Alcon Universal Ltd. | Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and methods of use |
CN1387505A (zh) | 1999-11-09 | 2002-12-25 | 爱尔康公司 | 含羟基二十碳四烯酸衍生物的组合物和用于治疗干眼病的方法 |
US6255343B1 (en) | 1999-11-09 | 2001-07-03 | Alcon Universal Ltd. | 2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use |
AU1226001A (en) | 1999-11-09 | 2001-06-06 | Alcon Universal Limited | Phospholipids of hydroxyeicosatetraenoic acid-like derivatives |
ATE296792T1 (de) | 1999-11-09 | 2005-06-15 | Alcon Inc | Benzenoidderivate von 15- hydroxyeicosatetraensäure und verfahren zur verwendung zur behandlung des trockenen auges |
US6552084B2 (en) | 1999-11-09 | 2003-04-22 | Alcon Universal Ltd. | Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders |
TR200201251T2 (tr) | 1999-11-09 | 2002-11-21 | Alcon, Inc. | Omega zinciri tadil edilmiş 15-hidroksieikosatetraenoik asit türevleri ve bunların göz kurumasının iyileştirilmesi için kullanım yöntemleri |
CA2386333A1 (en) | 1999-11-09 | 2001-05-17 | Alcon, Inc. | 3-heteroatom substituted and two carbon homologs 15-hete and methods of use |
CN1409639A (zh) | 1999-12-14 | 2003-04-09 | 杰南技术公司 | 应用TNF-α拮抗剂和LFA-1拮抗剂治疗LFA-1或TNF-α介导的疾病 |
AU2001288271A1 (en) * | 2000-08-17 | 2002-02-25 | Harrihar A. Pershadsingh | Methods for treating inflammatory diseases |
US20020151491A1 (en) | 2000-11-28 | 2002-10-17 | Jian-Dong Li | Composition and method for treating the over-production of mucin in diseases such as otitis media using an inhibitor of MUC5AC |
US20020132823A1 (en) * | 2001-01-17 | 2002-09-19 | Jiahuai Han | Assay method |
GB0108770D0 (en) * | 2001-04-06 | 2001-05-30 | Eisai London Res Lab Ltd | Inhibitors |
BR0209965A (pt) | 2001-05-21 | 2004-04-06 | Alcon Inc | Uso de inibidores de nf-kappab para tratar distúrbios do olho seco |
TR201815573T4 (tr) | 2002-05-28 | 2018-11-21 | Astrazeneca Ab | Topikal olarak uygulanabilir farmasötik preparasyon. |
CN1684738A (zh) * | 2002-09-20 | 2005-10-19 | 爱尔康公司 | 细胞因子合成抑制剂用于治疗干眼病的用途 |
-
2003
- 2003-08-26 CN CNA03822514XA patent/CN1684738A/zh active Pending
- 2003-08-26 BR BR0314603-0A patent/BR0314603A/pt not_active IP Right Cessation
- 2003-08-26 WO PCT/US2003/026689 patent/WO2004026406A1/en active Application Filing
- 2003-08-26 US US10/650,006 patent/US7026296B2/en not_active Expired - Fee Related
- 2003-08-26 AU AU2003278727A patent/AU2003278727A1/en not_active Abandoned
- 2003-08-26 KR KR1020057003759A patent/KR20050057175A/ko not_active Application Discontinuation
- 2003-08-26 JP JP2004537690A patent/JP2006502183A/ja active Pending
- 2003-08-26 MX MXPA05003063A patent/MXPA05003063A/es not_active Application Discontinuation
- 2003-08-26 EP EP03770254A patent/EP1542768A1/en not_active Withdrawn
- 2003-08-26 PL PL03374700A patent/PL374700A1/xx not_active Application Discontinuation
- 2003-08-26 CA CA002497977A patent/CA2497977A1/en not_active Abandoned
- 2003-09-04 TW TW092124459A patent/TW200404534A/zh unknown
- 2003-09-15 AR ARP030103339A patent/AR041262A1/es not_active Application Discontinuation
-
2005
- 2005-03-14 ZA ZA200502119A patent/ZA200502119B/en unknown
-
2006
- 2006-03-28 US US11/390,874 patent/US20060189541A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ZA200502119B (en) | 2006-09-27 |
CN1684738A (zh) | 2005-10-19 |
TW200404534A (en) | 2004-04-01 |
US7026296B2 (en) | 2006-04-11 |
AU2003278727A1 (en) | 2004-04-08 |
KR20050057175A (ko) | 2005-06-16 |
PL374700A1 (en) | 2005-10-31 |
MXPA05003063A (es) | 2005-05-27 |
US20040058875A1 (en) | 2004-03-25 |
JP2006502183A (ja) | 2006-01-19 |
EP1542768A1 (en) | 2005-06-22 |
WO2004026406A1 (en) | 2004-04-01 |
US20060189541A1 (en) | 2006-08-24 |
CA2497977A1 (en) | 2004-04-01 |
AR041262A1 (es) | 2005-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0314603A (pt) | Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos | |
BR0316350A (pt) | Diaminotriazóis úteis como inibidores de proteìna cinases | |
DE60327999D1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
CY1107531T1 (el) | Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου | |
ATE466580T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
ATE468336T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
DE60314603D1 (de) | Zusammensetzungen brauchbar als protein-kinase- inhibitoren | |
AR004321A1 (es) | Empleo de epinastina para el tratamiento de dolores. | |
BRPI0407993B8 (pt) | compostos inibidores de p38 e composições farmacêuticas compreendendo os mesmos | |
SE0101387D0 (sv) | Novel compounds | |
PT971713E (pt) | Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao | |
NO20002121L (no) | Benzotiazol-protein-tyrosin-kinaseinhibitorer | |
BR0308429A (pt) | Aroilpiridinonas monocìclicas como agentes antiinflamatórios | |
BRPI0506970A (pt) | derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior | |
PT1347971E (pt) | Inibidores tiazolilicos de tirosina-cinases da familia tec | |
BR0211274A (pt) | Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase | |
BR0109211A (pt) | Compostos com atividade 5-ht1a úteis para o tratamento de distúrbios da retina externa | |
ATE435858T1 (de) | Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen | |
TR200400526T4 (tr) | Göz kurumasının tedavisi için lipoksin A4 ve analogları | |
BR0015416A (pt) | Composições contendo derivados do ácido hidroxieicosa tetraenóico e métodos de uso no tratamento de distúrbios de olhos secos | |
BRPI0503445A (pt) | composição cosmética não corante, uso de uma composição e processo para tratamento cosmético dos cabelos | |
TR200201250T2 (tr) | Hidroksieikosatetraenoat tuzları, bileşimleri ve bunların göz kuruması bozukluklarının iyileştirilmesinde kullanım yöntemleri. | |
DE60233350D1 (de) | IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES | |
BRPI0415781A (pt) | método para o tratamento de diabetes em um paciente e kit farmacêutico | |
WO2003039453A3 (en) | Novel benzoyl peroxide compositions for the treatment of dermatological disorders and methods for their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 6A. E 7A. ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2069 DE 31/08/2010. |
|
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 31/506 (2006.01), A61P 27/02 (2006.01), A61K |